Pfizer to acquire Biohaven in $11.6bn deal to gain access to rimegepant
Pfizer has agreed to acquire Biohaven Pharmaceutical, a US-based biopharma company, in a deal worth around $11.6 billion, to gain access to the latter’s dual-acting migraine therapy NURTEC ODT (Rimegepant). As per the terms of the deal, Pfizer will pay $148.5 per share in cash to acquire the shares of the NYSE-listed Biohaven Pharmaceutical which […]